Transient hemiparesis associated with monoclonal CD3 antibody (OKT3) therapy.
OKT3 therapy for prevention or reversal of allograft rejection has been associated with a constellation of acute systemic side effects, defined as an OKT3 first-dose reaction. Specific neurologic syndromes, including aseptic meningitis and diffuse encephalitis, have also been observed. This report describes a 12-year-old girl with steroid-resistant renal allograft rejection who developed hemiparesis associated with initiation of OKT3 therapy.
Osterman
J D
JD
Department of Neurosciences, University of California School of Medicine, San Diego, USA.
Trauner
D A
DA
Reznik
V M
VM
Lemire
J
J
D000818:Animals; D002648:Child; D004569:Electroencephalography / Q000187:drug effects; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced / Q000175:diagnosis; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006429:Hemiplegia / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation; D051379:Mice; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects*; D009460:Neurologic Examination / Q000187:drug effects; D011183:Postoperative Complications / Q000139:chemically induced* / Q000175:diagnosis; D014718:Vesico-Ureteral Reflux / Q000601:surgery*
D016853:Muromonab-CD3